Rezpegaldesleukin Improves Atopic Dermatitis in Phase 2b TrialByShannon Heaning, Content AssociateAugust 25th 2026
The Multibillion-Dollar Molecule: How Zumilokibart’s Phase 2 Success Sparked AbbVie’s AcquisitionByMarie Bosslett, Assistant EditorAugust 24th 2026
Lebrikizumab Pregnancy Study Opens for Atopic DermatitisByShannon Heaning, Content AssociateAugust 20th 2026
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD ModelByShannon Heaning, Content AssociateAugust 20th 2026
Skin & Psych: Using Habit Loop Science to Interrupt the Itch-Scratch CycleByPatricia Delgado, DNP, AGPCNP, DCNP, PMHNP,Judson A. Brewer, MD, Ph.D.,Shannon Heaning, Content AssociateAugust 18th 2026